Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2014 | -1.11 Million USD | 30.02% |
| 2013 | -1.59 Million USD | 22.38% |
| 2012 | -2.06 Million USD | -152.47% |
| 2011 | 3.92 Million USD | 257.1% |
| 2010 | -2.49 Million USD | 39.34% |
| 2009 | -4.12 Million USD | 9.93% |
| 2008 | -4.57 Million USD | 14.42% |
| 2007 | -5.34 Million USD | -17.86% |
| 2006 | -4.53 Million USD | -84.27% |
| 2005 | -2.46 Million USD | -3.49% |
| 2004 | -2.37 Million USD | -17.84% |
| 2003 | -2.01 Million USD | -57.17% |
| 2002 | -1.28 Million USD | -19.44% |
| 2001 | -1.07 Million USD | -3.27% |
| 2000 | -1.04 Million USD | 54.02% |
| 1999 | -2.26 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2015 Q2 | -144 Thousand USD | 29.41% |
| 2015 Q1 | -204 Thousand USD | 6.42% |
| 2015 Q3 | -209 Thousand USD | -45.14% |
| 2014 Q3 | -213 Thousand USD | 19.62% |
| 2014 FY | -1.11 Million USD | 30.02% |
| 2014 Q2 | -265 Thousand USD | 37.35% |
| 2014 Q4 | -218 Thousand USD | -2.35% |
| 2014 Q1 | -423 Thousand USD | -3.68% |
| 2013 Q3 | -320 Thousand USD | 34.96% |
| 2013 Q4 | -408 Thousand USD | -27.5% |
| 2013 Q1 | -540 Thousand USD | -12.27% |
| 2013 Q2 | -492 Thousand USD | 8.89% |
| 2013 FY | -1.59 Million USD | 22.38% |
| 2012 Q2 | -613 Thousand USD | -12.27% |
| 2012 Q4 | -481 Thousand USD | -14.52% |
| 2012 FY | -2.06 Million USD | -152.47% |
| 2012 Q1 | -546 Thousand USD | -5.41% |
| 2012 Q3 | -420 Thousand USD | 31.48% |
| 2011 Q3 | -10.14 Million USD | -3589.45% |
| 2011 Q2 | -275 Thousand USD | 33.09% |
| 2011 Q1 | -411 Thousand USD | 14.38% |
| 2011 FY | 3.92 Million USD | 257.1% |
| 2011 Q4 | -518 Thousand USD | 94.89% |
| 2010 Q3 | -597 Thousand USD | 0.33% |
| 2010 Q1 | -822 Thousand USD | 4.86% |
| 2010 Q2 | -599 Thousand USD | 27.13% |
| 2010 Q4 | -480 Thousand USD | 19.6% |
| 2010 FY | -2.49 Million USD | 39.34% |
| 2009 Q1 | -1 Million USD | 2.34% |
| 2009 Q3 | -1.07 Million USD | 9.06% |
| 2009 FY | -4.12 Million USD | 9.93% |
| 2009 Q4 | -864 Thousand USD | 19.55% |
| 2009 Q2 | -1.18 Million USD | -17.98% |
| 2008 Q1 | -1.49 Million USD | -36.34% |
| 2008 Q4 | -1.02 Million USD | 1.16% |
| 2008 FY | -4.57 Million USD | 14.42% |
| 2008 Q3 | -1.03 Million USD | -2.07% |
| 2008 Q2 | -1.01 Million USD | 32.13% |
| 2007 Q4 | -1.09 Million USD | 17.38% |
| 2007 FY | -5.34 Million USD | -17.86% |
| 2007 Q1 | -1.21 Million USD | -28.84% |
| 2007 Q2 | -1.7 Million USD | -40.25% |
| 2007 Q3 | -1.32 Million USD | 22.01% |
| 2006 Q3 | -790 Thousand USD | 57.14% |
| 2006 Q4 | -943 Thousand USD | -19.37% |
| 2006 FY | -4.53 Million USD | -84.27% |
| 2006 Q2 | -1.84 Million USD | -92.18% |
| 2006 Q1 | -959 Thousand USD | -55.43% |
| 2005 Q2 | -641 Thousand USD | -23.51% |
| 2005 Q3 | -684 Thousand USD | -6.71% |
| 2005 Q4 | -617 Thousand USD | 9.8% |
| 2005 Q1 | -519 Thousand USD | 7.65% |
| 2005 FY | -2.46 Million USD | -3.49% |
| 2004 Q4 | -562 Thousand USD | -18.82% |
| 2004 Q2 | -589 Thousand USD | 21.88% |
| 2004 Q1 | -754 Thousand USD | -87.56% |
| 2004 FY | -2.37 Million USD | -17.84% |
| 2004 Q3 | -473 Thousand USD | 19.69% |
| 2003 Q1 | -585 Thousand USD | 15.83% |
| 2003 FY | -2.01 Million USD | -57.17% |
| 2003 Q4 | -402 Thousand USD | -42.05% |
| 2003 Q3 | -283 Thousand USD | 62.17% |
| 2003 Q2 | -748 Thousand USD | -27.86% |
| 2002 Q1 | -226 Thousand USD | -5.61% |
| 2002 FY | -1.28 Million USD | -19.44% |
| 2002 Q2 | -185 Thousand USD | 18.14% |
| 2002 Q4 | -695 Thousand USD | -290.45% |
| 2002 Q3 | -178 Thousand USD | 3.78% |
| 2001 Q4 | -214 Thousand USD | -79.83% |
| 2001 Q3 | -119 Thousand USD | 70.03% |
| 2001 Q2 | -397 Thousand USD | -18.51% |
| 2001 Q1 | -335 Thousand USD | -29.34% |
| 2001 FY | -1.07 Million USD | -3.27% |
| 2000 Q4 | -259 Thousand USD | -67.1% |
| 2000 Q1 | -320 Thousand USD | 0.0% |
| 2000 Q3 | -155 Thousand USD | 49.18% |
| 2000 Q2 | -305 Thousand USD | 4.69% |
| 2000 FY | -1.04 Million USD | 54.02% |
| 1999 FY | -2.26 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 16.207% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 77.817% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 93.73% |
| Nascent Biotech, Inc. | -2.22 Million USD | 49.818% |
| Rebus Holdings, Inc. | -664 Thousand USD | -68.524% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.367% |
| Qrons Inc. | -643.67 Thousand USD | -73.845% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -187.24% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.984% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -169.328% |
| Skye Bioscience, Inc. | -13.67 Million USD | 91.815% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.441% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 122.768% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -327.546% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.524% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 60.744% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 27.151% |
| Mesoblast Limited | -84.14 Million USD | 98.67% |
| Marizyme, Inc. | -34.08 Million USD | 96.717% |
| Genus plc | 6.4 Million USD | 117.484% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 111.486% |
| Pharming Group N.V. | -4.87 Million USD | 77.068% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 43.669% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -20.144% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 86.599% |
| ContraFect Corporation | -56.88 Million USD | 98.033% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 75.432% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 20.185% |
| IMV Inc. | -38.67 Million USD | 97.106% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 59.322% |
| MultiCell Technologies, Inc. | -722.81 USD | -154712.468% |
| ONE Bio Corp. | 13.68 Million USD | 108.179% |
| Accustem Sciences Inc. | -3.74 Million USD | 70.131% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.103% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -131.647% |
| Q BioMed Inc. | -3.44 Million USD | 67.524% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 131.61% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 57.412% |
| Biomind Labs Inc. | -1 Million USD | -10.836% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.964% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 61.43% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 83.168% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 39.98% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -3635.978% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.949% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 42.099% |
| GB Sciences, Inc. | -1.42 Million USD | 21.225% |
| Alpha Cognition Inc. | -9.7 Million USD | 88.471% |
| HST Global, Inc. | -140.9 Thousand USD | -694.141% |
| CSL Limited | 3.7 Billion USD | 100.03% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 0.525% |
| Halberd Corporation | -75.05 Thousand USD | -1391.006% |
| Enzolytics Inc. | -2.14 Million USD | 47.924% |
| Agentix Corp. | -1.37 Million USD | 18.426% |
| Resverlogix Corp. | -12.74 Million USD | 91.223% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 64.681% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.737% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -7.184% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 61.671% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 29.148% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 67.136% |
| AVAX Technologies, Inc. | 6.69 Million USD | 116.719% |
| Zenith Capital Corp. | -8.94 Million USD | 87.487% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.731% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -6323.282% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 54.425% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -552.442% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 44.183% |
| Kadimastem Ltd | -3.04 Million USD | 63.194% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -13.713% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 10.908% |
| BioStem Technologies, Inc. | -7.77 Million USD | 85.615% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -516.58% |
| LadRx Corporation | -3.82 Million USD | 70.735% |
| Cell Source, Inc. | -4.32 Million USD | 74.129% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -62.894% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -62.894% |
| NovAccess Global Inc. | -2.46 Million USD | 54.637% |
| Affymax, Inc. | -15.04 Million USD | 92.563% |
| Itoco Inc. | -919.14 Thousand USD | -21.744% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 73.599% |
| Mobile Lads Corp. | -554.55 Thousand USD | -101.785% |
| CytoDyn Inc. | -18.05 Million USD | 93.803% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -4345.769% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -408.456% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -98.15% |
| SYBLEU INC | -149.18 Thousand USD | -650.101% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 38.392% |
| International Stem Cell Corporation | -663 Thousand USD | -68.778% |
| Bioxytran, Inc. | -3.82 Million USD | 70.708% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2025.76% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -5401.475% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.914% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 30.841% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -52.072% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 64.031% |
| Neutra Corp. | -229.48 Thousand USD | -387.611% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 93.62% |
| PureTech Health plc | -146.19 Million USD | 99.235% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 94.793% |
| IXICO plc | -1.43 Million USD | 22.129% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 88.21% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.081% |
| CSL Limited | 3.81 Billion USD | 100.029% |
| Cellectis S.A. | -108.85 Million USD | 98.972% |